Ajinomoto Bio-Pharma Services vs Pharmaron: CDMO Comparison
How does Ajinomoto Bio-Pharma Services compare to Pharmaron for AAV manufacturing?
As of Nov 2026, Ajinomoto Bio-Pharma Services: no FDA inspections on file, 1 EMA/MHRA GMP certificate. Signal Score 83.5. Pharmaron: 5 FDA inspections (including 4 NAI, 1 VAI and 0 OAI), 1 EMA/MHRA GMP certificate. Signal Score 86.9. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.
Side-by-side comparison of Ajinomoto Bio-Pharma Services and Pharmaron on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Pharmaron has more FDA inspections on record (5 vs 0) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
On a 13-modality CDMO landscape, both Ajinomoto Bio-Pharma Services and Pharmaron qualify as AAV manufacturers; Pharmaron carries the higher composite Signal Score for AAV programs in this comparison.
What to evaluate for AAV programs
Both Ajinomoto Bio-Pharma Services and Pharmaron qualify as AAV CDMOs. When choosing between them for AAV programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Platform & scale
Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.
Capsid quality
Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.
Regulatory readiness
For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & timelines
AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.
Frequently asked: Ajinomoto Bio-Pharma Services vs Pharmaron
How does Ajinomoto Bio-Pharma Services compare to Pharmaron for AAV manufacturing?
On CDMO Signal's composite Signal Score, Ajinomoto Bio-Pharma Services is 84/100 and Pharmaron is 87/100; Ajinomoto Bio-Pharma Services has 0 FDA inspections on record vs 5 for Pharmaron; European coverage is 1 active EMA+MHRA certificate for Ajinomoto Bio-Pharma Services vs 1 for Pharmaron. Both are tracked in the CDMO Signal directory as AAV CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Ajinomoto Bio-Pharma Services or Pharmaron?
Both Ajinomoto Bio-Pharma Services and Pharmaron maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Ajinomoto Bio-Pharma Services has 0 FDA inspections on record; Pharmaron has 5.
How do Ajinomoto Bio-Pharma Services and Pharmaron compare on European GMP coverage?
Ajinomoto Bio-Pharma Services holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. Pharmaron holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for AAV manufacturing — Ajinomoto Bio-Pharma Services or Pharmaron?
Both Ajinomoto Bio-Pharma Services and Pharmaron are tagged as AAV CDMOs in our directory, so both are credible options for AAV programs. The most important differentiator for AAV selection is typically platform & scale: Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Ajinomoto Bio-Pharma Services carries a Signal Score of 84/100 and Pharmaron carries 87/100 — essentially tied for Pharmaron. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →